Saegis Pharmaceuticals Names Thorsten Melcher Vice President, Discovery.Business Editors & Health/Medical Writers BIOWIRE2K HALF MOON BAY, Calif.--(BUSINESS WIRE)--June 17, 2003 Saegis Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing medicines for the protection and enhancement of memory and mental function in diseases of the central nervous system, today announced that Thorsten Melcher, Ph.D., has joined the company as Vice President, Discovery. "Thorsten Melcher is uniquely qualified to lead our efforts to expand our portfolio of promising therapies for cognitive disorders," said Rodney Pearlman, Ph.D., president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Saegis Pharmaceuticals. "He has broad experience in target identification and drug discovery for diseases of the central nervous system, and in building and coordinating biotech discovery operations." Before joining Saegis Pharmaceuticals, Dr. Melcher was a founder and Chief Scientific Officer of EnVivo Pharmaceuticals, a drug discovery company focusing on neurodegenerative diseases neurodegenerative diseases diseases characterized by neurodegeneration. Lesions are microscopic only but in chronic disease with massive involvement there may be grossly visible atrophy of affected nervous tissue. using phenotypic screening approaches. Prior to that, Dr. Melcher was founder and Vice President of AGY AGY Agency Therapeutics, a genomics-based neuroscience company, where he was responsible for coordination of research, strategic planning and academic collaborations. Before joining AGY Therapeutics, Dr. Melcher worked in the research department of Lynx Therapeutics. Dr. Melcher received a M.S. degree in Biochemistry from the University and Medical School in Hannover, Germany, and a Ph.D. degree in Molecular Neurobiology Neurobiology Study of the development and function of the nervous system, with emphasis on how nerve cells generate and control behavior. The major goal of neurobiology is to explain at the molecular level how nerve cells differentiate and develop their from the Center of Molecular Biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller (ZMBH) at the University of Heidelberg, Germany. He is lead author on seminal publications in molecular neuroscience and inventor on a number of genomics and technology patents. "Utilizing a highly-efficient integrated discovery and development approach, Saegis has already completed two Phase II clinical trials on compounds acting on validated targets with intriguing mechanisms of action," said Dr. Melcher. "I am pleased to continue expansion of the company's Parallax parallax (pâr`əlăks), any alteration in the relative apparent positions of objects produced by a shift in the position of the observer. In astronomy the term is used for several techniques for determining distance. (TM) discovery platform to generate new candidates for clinical evaluation clinical evaluation Medtalk An evaluation of whether a Pt has symptoms of a disease, is responding to treatment, or is having adverse reactions to therapy ." Founded in 1999, Saegis Pharmaceuticals is a pioneer in the development of medicines that protect and enhance the function of the human mind. Through licensing activity, development partnerships and internal discovery programs, Saegis Pharmaceuticals is building a portfolio of compounds with activity against a range of disorders of the brain and central nervous system, including Alzheimer's disease, mild cognitive impairment mild cognitive impairment (MCI), n memory loss generally associated with aging; does not affect normal independent functioning of an individual. , and cognitive impairment associated with schizophrenia. Currently the Company has three orally available small molecule compounds in clinical development, two of which have already demonstrated efficacy and safety in humans. For more information, visit www.saegispharma.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion